Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Concentrated Growth Factors (CGF) is an autologous, blood-derived biological product consisting of a concentrated platelet-rich fibrin matrix. It is produced through a specialized centrifugation process of the patient's own venous blood, which isolates a fibrin scaffold rich in bioactive molecules. These include platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF). Developed by the Third Affiliated Hospital of Sun Yat-Sen University, CGF is being evaluated for the treatment of traumatic spinal cord injury (SCI). The therapeutic mechanism involves the release of these growth factors to promote angiogenesis, modulate the inflammatory microenvironment, and stimulate neural stem cell proliferation and axonal regeneration. In clinical applications, CGF is often prepared as a biofilm for surgical implantation at the site of the spinal cord lesion to facilitate motor and sensory recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Concentrated Growth Factors.